PHAT
$32.51
Phathom Pharmaceuticals
($.23)
(.70%)
PHAT
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.78)
Revenue:  $0.00 Mil
Tuesday
Nov 9
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PHAT reports earnings?
Beat
Meet
Miss

Where is PHAT's stock price going from here?
Up
Flat
Down
Stock chart of PHAT
Analysts
Summary of analysts' recommendations for PHAT
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo Grove, United States.